Honma Y, Yamamoto-Yamaguchi Y, Kanatani Y
Department of Chemotherapy, Saitama Cancer Center Research Institute, Ina, Japan.
Br J Cancer. 1999 Apr;80(1-2):96-103. doi: 10.1038/sj.bjc.6690327.
Vesnarinone, an oral cardiotonic, inhibited the growth of several human non-small cell lung carcinoma cell lines, and its anti-proliferative effects in vitro and in vivo were greatly enhanced by combination with glucocorticoids, but not other steroids. Simultaneous treatment with vesnarinone and dexamethasone is the most effective to evoke the synergistic effect in the growth inhibition of lung carcinoma EBC-1 cells. Dexamethasone and other glucocorticoids induced morphological changes in EBC-1 cells and these agents together with vesnarinone induced alkaline phosphatase activity, which is a typical marker of type II pneumocyte maturation. This treatment arrested the growth of the cells at the G1 phase, indicating that this treatment is cytostatic rather than cytotoxic. These results suggest that vesnarinone plus glucocorticoid might be useful in lung cancer therapy.
维司力农是一种口服强心剂,可抑制多种人非小细胞肺癌细胞系的生长,其在体外和体内的抗增殖作用与糖皮质激素联合使用时会大大增强,但与其他类固醇联合使用时则不会。维司力农与地塞米松同时治疗对肺癌EBC-1细胞的生长抑制产生协同作用最为有效。地塞米松和其他糖皮质激素可诱导EBC-1细胞发生形态变化,这些药物与维司力农一起可诱导碱性磷酸酶活性,这是II型肺细胞成熟的典型标志物。这种治疗使细胞生长停滞在G1期,表明这种治疗是细胞抑制性的而非细胞毒性的。这些结果表明,维司力农加糖皮质激素可能对肺癌治疗有用。